IBSA gladly confirms its participation in the 34th World Congress of the Société Internationale d’Urologie that will take place in Glasgow, Scotland, from 12th to 15th October 2014 (http://www.siucongress.org/2014/). IBSA will share a booth, completely focused on IALURIL® Prefill, with its local partner Aspire Pharma Ltd.
IBSA announces its attendance to the 23nd EADV Congress, European Academy of Dermatology and Venereology, which will take place in Amsterdam, October 8th to 12th, 2014 (http://www.eadvamsterdam2014.org). As one of the Company's investments in the field of dermatology, the event is the perfect occasion to meet partners and create new contacts at the booth which will feature Betesil® and Ialuset®/Ialuset® Plus lines. The booth will be shared with IBSA Farmaceutici Italia who is presenting the line of dermo-aesthetic products, mainly Viscoderm® and Aliaxin®.
IBSA is glad to announce its participation in the Annual Meeting of the European Respiratory Society (ERS - http://www.erscongress.org/) that will take place in Munich, Germany, Sept. 6/10, 2014.
IBSA will have a stand in the exhibition (Hall B1 – Stand E04) where there will be the opportunity to present Yabro®, aerosolized sodium hyaluronate for the treatment of respiratory diseases.
The company will also be present with a Satellite Symposium scheduled for Monday, September 8th, from 17.30 to 19.00. An international faculty of experts will discuss the rationale of the use of Hyaluronic Acid in the respiratory tract diseases and will present the clinical usefulness of Yabro® in upper and lower respiratory diseases (Symposium Program).
IBSA confirms the annual attendance to the EULAR Congress, that this year is going to take place in Paris from 11th to 14th June, 2014.
The European League Against Rheumatism (www.eular.org) is the most relevant congress worldwide in the field of rheumatic diseases.
The company will be present at the event with a Satellite Symposium scheduled for Thursday, June 12th, 8:15 to 9:45 (room 351), where we will put focus and we will debate on the current guidelines for the management of osteoarthritis (Program) .
The other activities are related to IBSA’s presence in the exhibition area with a booth where the complete company’s portfolio in the OA and pain areas (Condrosulf®, Sinovial®, Flector®), recently enlarged with the new and innovative 1-mL injectable formulation of diclofenac (Akis®/Dicloin®), will be presented to the medical community.
IBSA will attend the 29th Annual EAU Congress (http://www.eaustockholm2014.org/) with a Satellite Symposium scheduled on Saturday, April 12th, from 18.00 to 19.30 (room A11). Please find the final program here. At this occasion, a special focus will be made on GAGs therapy with IALURIL®.
In addition, we will also have a stand in the exhibition hall (stand no. B:08:09) where we’ll be glad to meet our partners and new contacts interested in our product in the urology field.
IBSA will attend the 6th Meeting of the Study in Multidisciplinary Pain Research (http://www.simpar.eu/simpar/), in co-partnership with IBSA Italy, with a Satellite Symposium scheduled on Friday, March 28th from 08.45 to 09.45 (room Lancisi) and entirely dedicated to the new and innovative subcutaneous injection of diclofenac (Akis®/Dicloin®) developed by IBSA. Please find the final program here.
IBSA will be also present with a stand in the exhibition area (stand no. 6/11), where we will have the occasion to present, together with Akis®/Dicloin®, our well-known line of products in the "pain area" (Condrosulf, Sinovial and Flector).
IBSA is glad to announce its attendance to the 16th World Congress of Gynecological Endocrinology which will take place in Florence, from the 5th to the 8th of March 2014 (http://isge2014.isgesociety.com/).
IBSA will attend the event with both a Satellite Symposium and booth area.
The Satellite Symposium is scheduled for Friday, March 7, from 13h15 to 15h15 and will focus on Endocrine Disorders and Female Infertility (Symposium Program)